PMA
P230042: Optune Lua
FDA PMA · Electrical tumor treatment fields for non-small cell lung cancer · Novocure, GmbH
Key facts
| PMA number | P230042 |
|---|---|
| Trade name | Optune Lua |
| Generic name | Electrical tumor treatment fields for non-small cell lung cancer |
| Applicant | Novocure, GmbH |
| Owner/operator | NOVOCURE GmbH |
| Product code | SDA |
| Approval date | Oct 15, 2024 |
| Docket number | 24M-5718 |
| Establishment registration | 3010457505 |
| FEI number | 3010457505 |
At a glance
- 1–9 Supplements
- Jul 1, 2026 Latest supplement decision
- No Withdrawn
- Yes Summary of safety and effectiveness on file
- 10–99 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: